Tenaya Therapeutics, Inc.
The company is committed to discovering, developing and commercializing therapies that address the root causes of heart disease. The company develops therapies through scientific advances in different but interrelated product platforms: gene therapy, cellular regeneration and precision medicine. The company is advancing development of its gene therapy product candidate, TN-201 (an adeno-associated virus-based gene therapy drug), among others. Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 140 |
Founded | 2016 |
Financials | |
|---|---|
Market Capitalization | 275.60M |
Revenue | |
Operating Income | -131.23M |
Operating Margin | |
Net Income | -124.58M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4916 / 5373 |
Sector : Healthcare | 944 / 1144 |
Industry : Biotechnology | 499 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3412 / 5565 |
Sector : Healthcare | 534 / 1182 |
Industry : Biotechnology | 263 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4888 / 5436 |
Sector : Healthcare | 947 / 1164 |
Industry : Biotechnology | 506 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3791 / 5330 |
Sector : Healthcare | 546 / 1174 |
Industry : Biotechnology | 196 / 667 |